biote (NASDAQ:BTMD) Posts Earnings Results, Beats Expectations By $0.01 EPS

biote (NASDAQ:BTMD) announced its quarterly earnings data on Wednesday. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01, FiscalAI reports. biote had a net margin of 14.07% and a negative return on equity of 21.42%. The business had revenue of $46.41 million for the quarter, compared to analyst estimates of $45.79 million.

Here are the key takeaways from biote’s conference call:

• Management plans to expand the commercial team and increase sales personnel from over 90 to approximately 120 and invest in its technology platform to improve the practitioner experience; these moves are intended to drive long-term growth but will raise near-term expenses.
• Q4 revenue was $46.4 million, down 6.9% year-over-year, with procedure revenue falling 13% to $31.8 million, driven by higher clinic/practitioner attrition and fewer net new clinic additions.
• Dietary supplement revenue grew 16% to $11.7 million (e-commerce-led) and management expects mid- to high-single-digit supplement growth in 2026, highlighting a complementary revenue stream.
• A voluntary recall of specific hormone pellet lots caused a $1.3 million inventory charge in Q4 and could create near-term gross margin and supply impacts, though the company says it is working with the FDA to manage the situation.
• For 2026 management guided to revenues above $190 million and adjusted EBITDA greater than $38 million, forecasting procedure revenue to decline mid-to-high single digits in H1 before returning to growth in H2 as investments and sales hiring take effect.

biote Stock Performance

biote stock traded up $0.03 during midday trading on Friday, reaching $1.57. 14,502 shares of the company’s stock were exchanged, compared to its average volume of 171,838. The stock’s 50-day simple moving average is $2.17 and its 200 day simple moving average is $2.64. The firm has a market cap of $71.46 million, a price-to-earnings ratio of 2.09 and a beta of 1.14. biote has a 52 week low of $1.54 and a 52 week high of $4.75.

Institutional Trading of biote

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in shares of biote by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 620,256 shares of the company’s stock worth $1,613,000 after acquiring an additional 8,016 shares during the last quarter. State Street Corp lifted its holdings in biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company’s stock valued at $1,560,000 after purchasing an additional 88,402 shares during the last quarter. Renaissance Technologies LLC boosted its position in biote by 5.7% during the fourth quarter. Renaissance Technologies LLC now owns 203,594 shares of the company’s stock worth $529,000 after purchasing an additional 10,900 shares during the period. Rothschild Wealth LLC acquired a new position in shares of biote in the fourth quarter valued at $380,000. Finally, Bridgeway Capital Management LLC raised its position in shares of biote by 142.1% in the second quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock valued at $487,000 after purchasing an additional 71,053 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on BTMD. Weiss Ratings reissued a “sell (d+)” rating on shares of biote in a research report on Monday, December 29th. B. Riley Financial dropped their target price on biote from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Thursday. Truist Financial set a $5.00 price target on biote in a research report on Wednesday, January 7th. TD Cowen lowered their price target on biote from $3.00 to $2.50 and set a “buy” rating on the stock in a research report on Thursday. Finally, National Bank Financial set a $2.50 price objective on biote in a research note on Thursday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, biote has a consensus rating of “Hold” and an average price target of $3.00.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.